Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853151 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 131
- Enrollment target
NCT00853151 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 131 participants.
The verdict
NCT00853151, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 131 participants
- Enrollment target
Study Summary
Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
Interventions
- DRUG LY2428757
- DRUG TT223
- DRUG Placebo for LY2428757
- DRUG Placebo for TT223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853151
The ClinicalTrials.gov registry entry for NCT00853151 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LY2428757 is the first listed.
NCT00853151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853151 about?
NCT00853151 is a clinical study titled "A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes". Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
What is the current status of trial NCT00853151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 131 participants. The study started on 2009-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00853151?
The interventions under investigation include: LY2428757 (DRUG), TT223 (DRUG), Placebo for LY2428757 (DRUG), Placebo for TT223 (DRUG).
Who is sponsoring clinical trial NCT00853151?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.